[{"address1": "201 Haskins Way", "address2": "Suite 230", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650-407-2376", "website": "https://www.cero.bio", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Brian G. Atwood", "age": 70, "title": "Chairman, CEO & Principal Executive Officer", "yearBorn": 1953, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel Mark Corey M.D.", "age": 44, "title": "Founder, CTO & Director", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Ross Carter", "age": 55, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Sikorski M.D., Ph.D.", "age": 60, "title": "Consultant", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 2.24, "open": 2.14, "dayLow": 2.0, "dayHigh": 2.24, "regularMarketPreviousClose": 2.24, "regularMarketOpen": 2.14, "regularMarketDayLow": 2.0, "regularMarketDayHigh": 2.24, "beta": -0.384, "volume": 261228, "regularMarketVolume": 261228, "averageVolume": 537867, "averageVolume10days": 3194010, "averageDailyVolume10Day": 3194010, "bid": 2.85, "ask": 2.9, "bidSize": 2900, "askSize": 900, "marketCap": 25649072, "fiftyTwoWeekLow": 2.0, "fiftyTwoWeekHigh": 12.8, "fiftyDayAverage": 7.09484, "twoHundredDayAverage": 9.92902, "currency": "USD", "enterpriseValue": 14705331, "floatShares": 5417960, "sharesOutstanding": 11929800, "sharesShort": 12092, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.00029999999, "heldPercentInsiders": 0.14811, "heldPercentInstitutions": 0.055970002, "shortRatio": 0.05, "impliedSharesOutstanding": 11929800, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -2516148, "52WeekChange": -0.7990654, "SandP52WeekChange": 0.29495108, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "CERO", "underlyingSymbol": "CERO", "shortName": "CERo Therapeutics Holdings, Inc", "longName": "CERo Therapeutics Holdings, Inc.", "firstTradeDateEpochUtc": 1638282600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "c96e7212-658f-3054-8625-d2aafea7c5eb", "messageBoardId": "finmb_1673740339", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.15, "recommendationKey": "none", "totalCash": 119014, "totalCashPerShare": 0.019, "totalDebt": 1395000, "quickRatio": 0.025, "currentRatio": 1.764, "returnOnAssets": -0.02548, "freeCashflow": -7951432, "operatingCashflow": -1710095, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-03-17"}]